Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection

Objective: In the quadrivalent (types 6/11/16/18) HPV vaccine (GARDASIL®/SILGARD®) clinical program, 73% of women aged 16-26 were naïve to all vaccine HPV types. In these women, prophylactic administration of the vaccine was highly effective in preventing HPV 6/11/16/18-related cervical disease. Of...

Full description

Autores:

Tipo de recurso:

Fecha de publicación:

2009

Institución:

Universidad del Rosario

Repositorio:

Repositorio EdocUR - U. Rosario

Idioma:

eng

OAI Identifier:

oai:repository.urosario.edu.co:10336/24233

Acceso en línea:

https://doi.org/10.4161/hv.5.10.9515
https://repository.urosario.edu.co/handle/10336/24233

Palabra clave:

Placebo
Silgard
Unclassified drug
Virus dna
Wart virus vaccine
Adolescent
Adult
Article
Bronchospasm
Controlled study
Drug efficacy
Drug fatality
Drug tolerability
Drug withdrawal
Female
Gastroenteritis
Genital system examination
Gynecologic disease
Headache
Human
Human papillomavirus type 11
Human papillomavirus type 16
Human papillomavirus type 18
Human papillomavirus type 6
Human tissue
Hypertension
Injection site reaction
Major clinical study
Papanicolaou test
Prophylaxis
Serology
Unspecified side effect
Uterine cervix disease
Verruca vulgaris
Adolescent
Adult
Cervix uteri
Female
Follow-up studies
Humans
Papillomavirus infections
Papillomavirus vaccines
Placebos
Vulva
Young adult
Cervical cancer
Hpv
Vaccine
viral
Antibodies

Rights

License

Abierto (Texto Completo)